Taysha Gene Therapies, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Taysha Gene Therapies reports increased R&D spending and net loss in Q1 2026, with cash reserves projected to fund operations into 2028.
NASDAQ
Taysha Gene Therapies reports significant clinical progress for TSHA-102 in Rett syndrome, securing Breakthrough Therapy designation and extending its cash runway into 2028 through a new term loan and equity offering.
NASDAQ
Taysha Gene Therapies reports positive clinical data for TSHA-102 in Rett syndrome and secures significant financing, extending cash runway into 2028.
NASDAQ
10-Q: Taysha Gene Therapies Reports Q1 2025 Financial Results, Highlights Rett Syndrome Program Progress
Taysha Gene Therapies reports a net loss for Q1 2025 while advancing its TSHA-102 clinical program for Rett syndrome.
NASDAQ
Taysha Gene Therapies reports a net loss of $25.5 million for Q3 2024, while highlighting progress in its TSHA-102 clinical trials for Rett syndrome.
NASDAQ
Taysha Gene Therapies reported its Q2 2024 financial results, highlighting progress in its Rett syndrome clinical trials and ongoing financial strategies.
NASDAQ
Taysha Gene Therapies reported a net loss of $24.1 million for the first quarter of 2024, while advancing its Rett syndrome clinical program.